This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pereira, A. M. Articles by Bax, J. J. Search for Related Content PubMed PubMed Citation Articles by Pereira, A. M. Articles by Bax, J. J.

Increased Prevalence of Regurgitant Valvular Heart Disease in Acromegaly

Departments of Endocrinology and Metabolism (A.M.P., S.W.v.T., F.R., J.W.A.S., J.A.R.), Cardiology (E.E.v.d.W., J.J.B.), and Pathology (H.M.), Leiden University Medical Center, 2300 RC Leiden, The Netherlands; and Cardiovascular Division (J.R.L.), University of Virginia, Charlottesville, Virginia 22908

Address all correspondence and requests for reprints to: Alberto M. Pereira, M.D., Ph.D., Department of Endocrinology and Metabolism, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands. E-mail: a.m.pereira{at}lumc.nl.

Cardiac involvement is common in acromegaly, but the prevalence of valvular abnormalities in patients with acromegaly has not been documented and is the topic of this study.

In a prospective study design, 40 consecutive patients with acromegaly and 120 control subjects (matched for age, sex, hypertension, and left ventricular systolic function) were studied. All patients and controls were evaluated using conventional two-dimensional and Doppler echocardiography.

Significant valve disease was more prevalent in acromegalics compared with controls (22% vs. 6.7%, respectively; P = 0.005). Aortic valve regurgitation (trace severity) was present in 30% of patients vs. 7% of controls (P < 0.001), and mitral regurgitation (moderate severity) was absent in controls but present in 5% of acromegalics (P = 0.014 vs. controls). Binary logistic regression analysis showed a significant impact only for disease duration on valvular disease, with an odds ratio of 1.19 (95% confidence interval, 1.028–1.376; P = 0.019).

Acromegaly is associated with an increased prevalence of regurgitant valvular heart disease. This is dependent on the duration of exposure to increased GH concentrations, with a 19% increase in odds per year. This increased prevalence of occult valvular disease indicates that these patients require appropriate follow-up care and monitoring, especially patients with inadequate control of GH overproduction.

A.M.P. and S.W.v.T. contributed equally to this study.

Abbreviation: MMP, Matrix metalloproteinase.

This article has been cited by other articles:

				M. Kars, V. Delgado, E. R. Holman, R. A. Feelders, J. W. A. Smit, J. A. Romijn, J. J. Bax, and A. M. Pereira Aortic Valve Calcification and Mild Tricuspid Regurgitation But No Clinical Heart Disease after 8 Years of Dopamine Agonist Therapy for Prolactinoma J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3348 - 3356. [Abstract] [Full Text] [PDF]

				A. A van der Klaauw, J. J Bax, J. W A Smit, E. R Holman, V. Delgado, G. B Bleeker, N. R Biermasz, F. Roelfsema, J. A Romijn, and A. M Pereira Increased aortic root diameters in patients with acromegaly Eur. J. Endocrinol., August 1, 2008; 159(2): 97 - 103. [Abstract] [Full Text] [PDF]

				A. Colao, J. Marek, M. I. Goth, P. Caron, J. M. Kuhn, F. M. Minuto, and N. J. Weissman No Greater Incidence or Worsening of Cardiac Valve Regurgitation with Somatostatin Analog Treatment of Acromegaly J. Clin. Endocrinol. Metab., June 1, 2008; 93(6): 2243 - 2248. [Abstract] [Full Text] [PDF]

				M. Sandrock, A. Schmidt-Trucksass, D. Schmitz, A. Niess, and H.-H. Dickhuth Influence of Physiologic Cardiac Hypertrophy on the Prevalence of Heart Valve Regurgitation J. Ultrasound Med., January 1, 2008; 27(1): 85 - 93. [Abstract] [Full Text] [PDF]

				S. Melmed Acromegaly N. Engl. J. Med., December 14, 2006; 355(24): 2558 - 2573. [Full Text] [PDF]

				S W van Thiel, J J Bax, N R Biermasz, E R Holman, D Poldermans, F Roelfsema, H J Lamb, E E van der Wall, J W A Smit, J A Romijn, et al. Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly Eur. J. Endocrinol., August 1, 2005; 153(2): 231 - 238. [Abstract] [Full Text] [PDF]

				N. R. Biermasz, A. M. Pereira, J. W. A. Smit, J. A. Romijn, and F. Roelfsema Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2731 - 2739. [Abstract] [Full Text] [PDF]

				M. J. E. Walenkamp, M. Karperien, A. M. Pereira, Y. Hilhorst-Hofstee, J. van Doorn, J. W. Chen, S. Mohan, A. Denley, B. Forbes, H. A. van Duyvenvoorde, et al. Homozygous and Heterozygous Expression of a Novel Insulin-Like Growth Factor-I Mutation J. Clin. Endocrinol. Metab., May 1, 2005; 90(5): 2855 - 2864. [Abstract] [Full Text] [PDF]